Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc99m-tilmanocept Imaging in NASH
NCT03332940Phase 1Terminated
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Dec 2017
- Primary completion
- Mar 2019
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of technetium tc 99m tilmanocept in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoint: Adverse Drug Reaction at 5 days. Started Dec 2017; status: terminated.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03332940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332940.